-
What should I do if CAR-T treatment for lymphoma patients fails?
Time of Update: 2021-03-22
Recently, the team of the Department of Hematology at the Second Affiliated Hospital of Zhejiang University School of Medicine published a paper in the Journal of Hematology & Oncology, demonstrating the use of the new CD19-PD-1/CD28-CAR-T technology for the rescue treatment of CD19-CAR-T After treatment fails, patients with diffuse large B-cell lymphoma (DLBCL) can achieve good results.
-
Gut: The risk of gastrointestinal cancer in patients with non-alcoholic fatty liver disease increases up to 2 times!
Time of Update: 2021-03-22
This study conducted a meta-analysis of observational studies to quantify the degree of association between NAFLD and the risk of extrahepatic cancer.
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
-
Systemic Treatment of Advanced Liver Cancer: Yesterday, Today and Tomorrow｜Reviewing the Past and Knowing the New
Time of Update: 2021-03-21
The study showed that sorafenib compared with placebo treatment of advanced HCC prolonged the median overall survival (OS) period by 2.
-
JAMA: Expanded scope of lung cancer screening
Time of Update: 2021-03-21
New evidence supporting the guidelines The 2013 USPSTF’s recommendation statement is based on the results of the National Lung Screening Test (NLST), which found that in 53,454 people aged 55 to 74, currently smoking or quitting smoking (within the past 15 years) ) And among American adults with 30 packs/year, 3 rounds of low-dose CT and chest X-ray examinations are performed every year, and the lung cancer mortality rate is relatively reduced by 20%.
-
2021 EBMT | Anti-CD19 CAR-T therapy for children with R/R ALL: Fractionated infusion can improve safety while maintaining treatment effectiveness
Time of Update: 2021-03-21
The interim analysis of the 02 study results in cohort 1 showed that the severe (grade 3-5) CRS and neurotoxicity that occurred at the time of enrollment of the children were only related to a higher leukemia burden (primitive cells in the bone marrow> 20%) (P=0.
-
Zheng Junke, Shanghai Jiaotong University and other teams reveal the key role of oxidative phosphorylation in B-cell acute lymphoblastic leukemia
Time of Update: 2021-03-21
The study used the SoNar transgenic mouse strain to prove that B-cell acute lymphoblastic leukemia (B-ALL) cells have an advantage in the use of oxidative phosphorylation.
-
Small Methods from the Nanomedicine Team of the Third Affiliated Hospital of Sun Yat-sen University: Nanomaterials promote the treatment of cancer by adoptive cell therapy
Time of Update: 2021-03-21
Adoptive cellular transfer (ACT) therapy is a tumor treatment method in which immune cells are first separated from the patient's body, activated, expanded and modified in vitro, and then reinjected into the patient's body for treatment.
WILEY paper information: Engineering Nano-Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment.
-
Eur Radiol: What exactly affects the prognosis of patients after stereotactic radiofrequency ablation of liver tumors?
Time of Update: 2021-03-21
Colorectal cancer Recently, a study published in European Radiology evaluated the frequency of major complications after multi-probe stereotactic radiofrequency ablation (SRFA) in a large cohort of patients over the past 15 years, and clarified the risk factors for adverse events.
-
Lung Cancer Innovation Forum: Multi-location linkages, big names gather to talk about the progress of lung cancer treatment
Time of Update: 2021-03-21
We hope that with our joint efforts, we will build a patient-centric ecosystem and help a healthy China!" The main venue of the Lung Cancer Innovation Forum is divided into two chapters: targeted therapy and immunotherapy, bringing together well-known domestic experts to share the hotspots and latest developments in this field.
-
Cancer treatment target: EphA2
Time of Update: 2021-03-21
Some Eph receptors, especially EphA2, have attracted widespread attention because they have been shown to play an important role in the regulation of cancer occurrence and tumor progression (Figure 1).
In addition, EphA2 has ligand-independent kinase activity in cancer cells.
-
One article summary│Bladder cancer biology development and related treatment progress
Time of Update: 2021-03-21
Although the research of TME is still in the emerging stage in the field of bladder cancer, the advancement of imaging and single-cell analysis technology helps to further clarify the importance of stromal and infiltrating immune cell types in cancer progression and therapeutic intervention.
-
Eur Radiol: Differential diagnosis of CT and MR between pancreatoblastoma and solid pseudopapillary tumor in children
Time of Update: 2021-03-21
Check the size, boundary, calcification, hemorrhage, solid/cystic component ratio, intratumoral blood vessels , tumor capsule, pancreatic duct dilatation, peripancreatic vascular invasion, distant metastasis, and apparent diffusion coefficient (ADC) of the two groups of lesions Value and identify key diagnostic characteristics.
-
A retrospective analysis of the three countries found that: insufficient adjuvant therapy for patients with stage IB-IIIA NSCLC will affect the long-term survival benefits of patients
Time of Update: 2021-03-21
2% of 258 patients in France, Germany and the United Kingdom received adjuvant system therapy, of which cisplatin/vinorelbine is the most commonly used in these three countries The adjuvant treatment plan.
-
2021 EBMT Voice of China | ATLG vs rATG prognostic comparison of R/R and high-risk B-ALL patients with CAR-T bridge transplantation
Time of Update: 2021-03-21
Research conclusions In patients who received CD19-CAR-T therapy bridging haplo-SCT therapy, the clinical results of the two types of ATG (ATLG and rATG) in GVHD prevention and viral infection were similar.
-
[Phase 4] Standardized Diagnosis and Treatment Courses for Prostate Cancer——Molecular Classification and Precision Treatment of Prostate Cancer
Time of Update: 2021-03-21
The fourth "Prostate Cancer Standardized Diagnosis and Treatment Course" The fourth period is "Prostate Cancer Molecular Typing and Precision Treatment" brought by Professor Zeng Hao from West China Hospital of Sichuan University: Click to watch the highlights video!
-
FGFR: Growth Factor Receptor Tumor Targeting New Direction Differentiated Immunity (2)
Time of Update: 2021-03-21
FGFR targeted drugs Fibroblast growth factor receptor family (FGFR) belongs to the receptor kinase family, which includes four receptor subtypes (FGFR-1, 2, 3 and 4) encoded by four closely related genes And some heterogeneous molecules, they form a ternary complex with 18 different fibroblast growth factors (FGF), and then trigger a series of signal transduction pathways, participate in the regulation of physiological processes in the organism, such as: embryonic development, wounds Healing and angiogenesis, etc.
-
Professor Xu Jianming: KEYNOTE-181 brings a historic breakthrough for the treatment of esophageal cancer
Time of Update: 2021-03-21
KEYNOTE-181 clinical study of the Chinese subgroup data analysis results show that pembrolizumab in the second-line treatment of PD-L1 positive [comprehensive positive score (CPS) ≥ 10] inoperable locally advanced and metastatic esophageal cancer for 12 months The survival rate reached 53%, which was more than 3 times that of the chemotherapy group (16.
-
Prevention of liver cancer see authoritative guidelines | 2021 version of primary liver cancer secondary prevention consensus recommendations
Time of Update: 2021-03-21
Recently, the famous Hong Kong movie star Wu Mengda and the well-known mainland musician Zhao Yingjun have passed away from liver cancer, and the world can't help but sigh. Hepatocarcinoma is known
-
2021 EBMT | CAR.CD123-NK cells are expected to bring new treatment strategies for CD123-positive children with AML
Time of Update: 2021-03-21
The high expression of CD123 in AML leukemia stem cells is a potential new target for CAR cell therapy.
9%) in vitro, and showed significant anti-leukemia activity against CD123-positive tumor cells (Figure A below) ).
-
Prof. Zhixiang Shen: Gerritinib opens a new era of targeted therapy for FLT3 mutant AML
Time of Update: 2021-03-21
On February 4, 2021, Sigatan® (geritinib fumarate tablets) was approved by the National Medical Products Administration (NMPA) for the treatment of FLT3 mutation-positive relapsed or refractory AML, marking China FLT3 mutant AML patients usher in the first targeted therapy drug, opening a new era of targeted therapy.
